Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ekxjCfbwocfCdCnhuoVW

February 19, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
 
  • Obama administration to unveil 10-year brain-mapping project
    The Obama administration is looking to unveil next month a 10-year project to map the active human brain, called Brain Activity Map. Scientists say the project may pave the way for the development of technologies that will help improve understanding of neurological conditions such as Alzheimer's and Parkinson's disease. The project, which may be worth $3 billion over 10 years, may also allow for the creation of national brain "observatories," akin to astronomical observatories. The New York Times (tiered subscription model) (2/17) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Your initiatives. Our technology. Together, we can reduce radiation exposure.
Utilizing a fully shielded, mobile design, the MEDRAD™ Intego™ enables sites to infuse doses-on-demand from a multi-dose vial, providing clinicians with added protection and more accurate, repeatable, patient-specific dosing. Click here to learn more.
  Clinical News & Research 
  • Alzheimer's beyond amyloidosis: WMHs matter, too, study finds
    Amyloid accumulation may play a role in the development of Alzheimer’s disease, but it may not be enough to diagnose the disease, according to a study published in JAMA Neurology. Small-vessel cerebrovascular disease, which manifests as white matter hyperintensities, may also play a role in the development of the disease, the study said, and the combined factors appear to be involved in manifestation of disease. The researchers used C-11-PIB-PET imaging to detect amyloid buildup and structural MRI to measure WMH. "The findings suggest a role of small-vessel cerebrovascular disease in the clinical presentation of AD and point to the importance of incorporating WMH into the formulation of pathogenic models of the disease," the researchers wrote. MolecularImaging.net (2/17) LinkedInFacebookTwitterEmail this Story
 
  Industry Report 
  News from the Field 
  • Spectroscopy method detects fake malaria-fighting tablets
    Researchers from the U.K. said a method related to NMR spectroscopy, known as nuclear quadrupole resonance spectroscopy, can be an effective way to detect fake drugs. Researchers used the technique to detect fake Metakelfin, an antimalarial drug, finding that the counterfeit tablets contained only 43% of the necessary amount of sulfalene. Researchers hope the method can be modified to identify other counterfeit drugs and harnessed for the development of a portable fake-drug detector. The findings were published in Analytical Chemistry. Chemical & Engineering News (2/18) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • CMS proposes MLR requirements for Medicare Advantage, Part D
    A CMS rule proposed Friday lays out medical loss ratio requirements for Medicare plans under the Affordable Care Act. Medicare Part D and Medicare Advantage plans must spend 85% of revenue on quality improvements, prescription drugs, clinical services and other clear patient benefits, the CMS said. Plans that fail to meet the requirements would see enrollment sanctions after three years in a row, and contracts would be terminated after failing to meet requirements for five consecutive years. MedPage Today (free registration) (2/18) , PharmaTimes (U.K.) (2/18) LinkedInFacebookTwitterEmail this Story
  • Drug price controls would harm innovation
    Letting the government negotiate prices for Medicare Part D would be a step toward government control of drug prices and would keep future cures off the shelves, writes Dr. Adam Dorin, president and founder of America's Medical Society. America's health costs are a result of the nation's role in leading the way in introducing life-saving innovations, he writes. The Washington Times/Communities blog (2/17) LinkedInFacebookTwitterEmail this Story
 
  Advancing Health Care 
  • Gift bans influence prescribing of brand-name drugs, studies find
    Physicians who attended medical schools that restricted industry-provided meals and gifts were less likely to prescribe brand-name drugs than those whose schools did not implement such restrictions, a study in BMJ revealed. Another study published in Medical Care supported the findings, noting lower prescribing of widely promoted, brand-name drugs after gift bans became common. American Medical News (free content) (2/18) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
Everything that lives, lives not alone, nor for itself."
--William Blake,
British poet and painter


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information